Compare iShares MSCI South Africa ETF (EZA) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Africa ETF vs Organon & Co. Common Stock — how do they compare? iShares MSCI South Africa ETF trades at $63.18 (market cap $465.74M), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Organon & Co. Common Stock is far larger — about 7.8× iShares MSCI South Africa ETF's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while iShares MSCI South Africa ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI South Africa ETF for 73 Days and Organon & Co. Common Stock for 0 Days on average.
| EZA | OGN | |
|---|---|---|
Market Cap | $465.74M | $3.62B |
Volume | 245,187 | 2,892,999 |
Sector | Broad Market / Factor | Health |
52-Week High | $81.60 | $13.81 |
52-Week Low | $60.43 | $5.70 |
Typical Hold Time | 73 Days | 0 Days |
Enterprise Value | — | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EZA trades at $64.32, up 0.86% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF, which tracks South African equities, faces headwinds from global reflation and higher capital costs impacting its financial and commodity-heavy holdings. Recent news highlighted a brief move above the 50-day average, but macro concerns dominate the narrative.
The outlook remains cautious due to exposure to volatile sectors like gold and banking amid rising rates. Investment opportunity hinges on South Africa's economic stability, but risks include commodity price pressures and unfavorable yield dynamics. Investor sentiment is neutral to bearish, with technicals suggesting near-term resistance at $64.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI South Africa ETF
EZA is a country-specific ETF that tracks the South African equity market. It provides exposure to large and mid-cap companies across key sectors like materials and financials, with top holdings such as AngloGold Ashanti and Naspers.
Read more on EZA →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
